Artizan Biosciences Closes $11M Series A-2 Financing And Enters Option And License Agreement With Biohaven Therapeutics
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease
Series A-2 led by Hatteras Venture Partners and Biohaven
Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors
NEW HAVEN, Conn., March 1, 2021-- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota, today announced the company has raised $11 million in a Series A-2 financing led by ...